...
首页> 外文期刊>Journal of psychopharmacology >Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.
【24h】

Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia.

机译:文拉法辛和阿米替林对患有或不伴有忧郁症的重度抑郁症患者的双盲比较。

获取原文
获取原文并翻译 | 示例

摘要

The purpose of this study was to compare the efficacy and tolerability of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. This was an 8-week, multicentre, randomized, double-blind, parallel-group comparison of venlafaxine and amitriptyline. Outpatients with DSM-IV major depression, a minimum score of 20 on the 21-item Hamilton Depression Rating Scale (HAM-D), and depressive symptoms for at least 1 month were eligible. Patients were randomly assigned to venlafaxine or amitriptyline, both drugs titrated to a maximum of 150 mg/day until study day 15. The primary efficacy variables were the final on-therapy scores on the HAM-D, Montgomery-Asberg Depression Rating Scale and Clinical Global Impression severity scales. Data were evaluated on an intent-to-treat basis using the LOCF method. One hundred and 16 patients were randomized, and 115 were evaluated for efficacy. Both drugs showed efficacy in the treatment of depression with or without melancholia. No significant differences were noted between treatments for any efficacy parameter. However, significantly (p < 0.05) more patients in the amitriptyline group had at least one adverse event. These results should support the efficacy and tolerability of venlafaxine in comparison with amitriptyline for treating major depression with or without melancholia.
机译:这项研究的目的是比较文拉法辛和阿米替林在患有或不患有忧郁症的重度抑郁患者中的疗效和耐受性。这是文拉法辛和阿米替林的8周,多中心,随机,双盲,平行组比较。 DSM-IV重度抑郁,门诊21项汉密尔顿抑郁等级量表(HAM-D)最低分数为20,且抑郁症状持续至少1个月的门诊患者符合条件。患者被随机分配到文拉法辛或阿米替林,两种药物的最高滴度均为150 mg /天,直至研究第15天。主要疗效变量是HAM-D,蒙哥马利-阿斯伯格抑郁量表和临床上的最终治疗评分。整体展示严重度等级。使用LOCF方法按意向性评估数据。随机将116例患者进行疗效评估,其中115例进行了评估。两种药物在治疗伴有或不伴有忧郁症的抑郁症中均显示出疗效。对于任何功效参数,治疗之间均未发现明显差异。但是,阿米替林组中有显着(p <0.05)更多的患者发生了至少一项不良事件。这些结果应支持文拉法辛与阿米替林治疗伴有或不伴有忧郁症的重度抑郁症的疗效和耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号